Cabaletta Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cabaletta Bio, Inc. (CABA) on October 27, 2025. The filing discloses new clinical data and development updates for the company's lead product candidate, rese-cel (resecabtagene autoleucel), presented at the American College of Rheumatology (ACR) Convergence 2025. The data covers three ongoing Phase 1/2 trials: RESET-Myositis, RESET-SSc (Systemic Sclerosis), and RESET-SLE (Systemic Lupus Erythematosus).
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical developments and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
The filing details significant clinical progress across three therapeutic areas:
- RESET-Myositis: Complete adult Phase 1/2 data from 13 patients (6 DM/ASyS, 6 IMNM, 1 juvenile). In the DM/ASyS cohort, all 4 patients meeting key criteria achieved immunomodulatory-free total improvement score (TIS) responses at week 16. The company is initiating a registrational cohort for DM/ASyS, expecting to enroll 14 patients. In the IMNM cohort, 2 of 4 patients achieved TIS responses at week 24.
- RESET-SSc: Preliminary data from 6 patients. All 4 patients with at least 3 months of follow-up achieved an rCRISS-25 response off immunomodulators and steroids. Safety included low-grade cytokine release syndrome (CRS) in 3 patients and one grade 3 ICANS event.
- RESET-SLE: Preliminary data from 9 patients (5 non-renal SLE, 4 lupus nephritis). All 9 patients were off immunomodulators. Three of 4 SLE patients achieved DORIS (remission), and 3 of 4 LN patients showed renal response. The company is expanding the trial to include a "no preconditioning" dose-escalation cohort, with initial data anticipated in 2026.
Guidance, Outlook, and Risks
Management expects to initiate enrollment in the registrational DM/ASyS cohort in the current quarter (Q4 2025). The company anticipates FDA alignment on registrational cohort designs for lupus and systemic sclerosis in 2025. The filing includes extensive forward-looking statements regarding the potential for rese-cel to serve as a curative targeted cell therapy. Key risks cited include the uncertainty of clinical trial results, regulatory approval timelines, potential safety issues, and the risk that interim data may not predict future outcomes.
Investor Verification Checklist
- Verify the specific inclusion criteria and primary endpoints for the newly initiated DM/ASyS registrational cohort.
- Confirm the timeline for FDA alignment meetings regarding the RESET-SSc and RESET-SLE registrational designs.
- Monitor the safety profile of the new "no preconditioning" cohort in the RESET-SLE trial, particularly regarding B cell depletion efficacy without lymphodepleting chemotherapy.
- Review the durability of responses in the IMNM cohort, noting the observation of CD19-negative long-lived plasma cells in non-responders.
- Assess the company's cash runway and capital requirements to support the expansion of registrational trials and the new dose-escalation cohorts.